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Introduction
Topical drug delivery across the skin can offer many advantages, such as confer sustained drug
release, lower fluctuations in plasma drug levels, circumvent first-pass metabolism, improve patient
compliance, and provide local (dermal), or systemic (transdermal) effects (Schäfer-Korting et al.,
2007; El Maghraby et al., 2008). However, the barrier function of the skin, exerted by the horny
layer of the stratum corneum, impairs the penetration and absorption of drugs (Bouwstra and
Ponec, 2006). This layer prevents the penetration of hydrophilic compounds much more efficiently
as compared to lipophilic compounds (Bouwstra et al., 2003; Bouwstra and Ponec, 2006). Therefore,
there has been wide interest in exploring new techniques to increase drug absorption through the
skin. Novel topical drug delivery systems, with the use of nanotechnology in dosage form design,
have been used to facilitate overcoming the skin barrier. This article will summarize recent findings
of lipid-based nano-delivery systems for skin delivery of drugs and bioactives agents.
Skin Barrier and Permeability
The main barrier of the skin is located in the outermost layer, the stratum corneum. The stratum
corneum consists of corneocytes surrounded by lipid regions. As most drugs applied onto the
skin permeate along the lipid domains, the organization and composition of the lipid component
is considered to be very important for the skin barrier function. This layer generally consists of
long chain ceramides, free fatty acids and cholesterol (Bouwstra et al., 2003; Schäfer-Korting et al.,
2007). Additional defensive features of the stratum corneum that have a negative influence on skin
penetration, include the low pH, the presence of enzymes on the skin, and the transcutaneous
concentration gradient (Geusens et al., 2011). The factors that affect the skin absorption of topically
applied agents are size, shape, superficial charges, lipophilicity, presence of penetration enhancers,
type of formulation, and physical state of the stratum corneum (Verma et al., 2003a).
Skin permeability of topical agents is often assessed using ex vivo (human or animal skin) or
in vitro (e.g., parallel artificial membrane permeability assay—PAMPA) techniques (El Maghraby
et al., 2008; Yu et al., 2015). As the majority of studies have generated data from animal models,
this has posed a number of issues in relation to significance of the results to humans, as skin
permeability differs between species. For example, mouse skin is much thinner and contains more
hair follicles—increasing the odds for transdermal delivery (El Maghraby et al., 2008; Geusens
et al., 2011). The use of skin PAMPA technology for high-throughput analysis of topical drug
permeability has shown promise in assessing passive absorption processes of free drugs (Sinkó
et al., 2012). However, the use of artificial membranes for evaluating nano-delivery systems is still
limited, with more research required to establish more accurate and consistent results. In general,
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the different experimental parameters such as formulation,
experimental setting, species, gender, and age of skin donors,
often make it challenging to compare similar studies (Geusens
et al., 2011).
Furthermore, diseased skin is often characterized by a
reduce barrier function and an altered lipid composition and
organization. In diseased states, often the activity of one or
more enzymes involved in the synthesis of the barrier lipids
is altered compared to that in normal skin. Percutaneous
inflammation can also influence the permeability of topical
agents (Bouwstra et al., 2003; Bouwstra and Ponec, 2006). It
should be kept in mind that due to the complexity and inter-
individual variability associated with different skin conditions,
the use of native stratum corneum does not allow detailed
systematic studies.
Interaction of Lipid-based Nano-delivery
Systems with the Skin
The exact mechanisms by which vesicular systems deliver drugs
into intact skin are not yet fully understood. Some proposed
mechanisms of action of such vesicles in the modulation of
skin permeability have previously been reviewed (Dubey et al.,
2007; Elsayed et al., 2007; El Maghraby et al., 2008; Nounou
et al., 2008; El Maghraby and Williams, 2009). Four general
mechanisms have been reported, which include (i) intact drug-
laden vesicle penetration into the different layers of the skin; (ii)
lipid vesicles acting as penetration enhancers via their skin lipid-
fluidizing property; (iii) direct carrier-skin drug exchange by
“collision complex transfer” between the drug intercalated in the
lipid bilayer and the surface phase of the stratum corneum; and
(iv) lipid vesicle-mediated enhanced transdermal drug delivery
via appendageal pathways (e.g., hair follicles and sweat ducts)
(Dubey et al., 2007; Elsayed et al., 2007; El Maghraby et al.,
2008; Nounou et al., 2008; El Maghraby and Williams, 2009).
The transepidermal pathway across intact skin contains two
micropathways—the intercellular and transcellular route. As
both pathways involve transport through intercellular lipids,
research has focused on understanding the composition and
organization of these structures in the stratum corneum (El
Maghraby et al., 2008).
The mechanism(s) involved is dependent on the formulation,
in particular factors such as composition and particle size.
For example, particle size of lipid vesicles has a significant
influence on delivery of substances into the skin (Verma et al.,
2003a,b). Generally, large vesicles with a size ≥600 nm are not
able to deliver their contents into deeper layers of the skin.
These vesicles tend to stay in or on the stratum corneum
and may form a layer of lipid after drying. Vesicles with
a size ≤300 nm are able to deliver their contents to some
extent into the deeper layers of the skin; however those with a
size ≤70 nm have shown maximum deposition of contents in
both viable epidermal and dermal layers (Verma et al., 2003a).
Whether these lipid vesicles can pass intact into deeper layers
of the skin or not is still a subject of debate (Bouwstra et al.,
2003). Nanoparticles below 6–7 nm or 36 nm in size may be
absorbed through the lipidic transepidermal routes or aqueous
pores, respectively. In contrast, larger agents (10–210 nm)
may preferentially penetrate through the transfollicular route
(Geusens et al., 2011).
Lipid-based Nano-delivery Systems for
Topical Drug Delivery
Liposomes are well-established nano-sized lipid-vesicles that
offer potential value in topical drug delivery. They are formed
by one or multiple lipid bilayers that enclose a discrete aqueous
phase (Figure 1). Liposomes offer many advantages as drug
delivery carriers—for example they are biodegradable, non-toxic,
and are able to encapsulate both water-soluble and lipophilic
substances (Hua and Wu, 2013; Hua, 2014; Bozzuto and
Molinari, 2015). They are similar to the epidermis with respect
to their lipid composition, which enables them to penetrate
the epidermal barrier to a greater extent compared to other
conventional dosage forms. The majority of topically applied
liposomes onto the skin will accumulate in the upper layers of the
stratum corneum and function more as a “reservoir” providing
a more localized action (Kirjavainen et al., 1999; Honeywell-
Nguyen and Bouwstra, 2005; Cosco et al., 2008; Geusens et al.,
2011).
In order to further enhance skin permeation of encapsulated
molecules, alterations in composition and structure of
conventional liposomes were made to generate new classes
of lipid vesicles with flexible and ultradeformable properties—in
particular niosomes, Transfersomes R© and ethosomes (Figure 1).
Niosomes are non-ionic surfactant vesicles made up of single
chain surfactant molecules in combination with cholesterol.
These nanoparticles generally resemble the same characteristics
as that of liposomes, however are considered more stable (Vora
et al., 1998). Niosomes were thought to improve the horny layer
properties, both by reducing transepidermal water loss and by
increasing smoothness through replenishment of lost skin lipids
following fusion to corneocytes (Hofland et al., 1995; Geusens
et al., 2011). Niosomes have the ability to modify the structure
of the stratum corneum through their surfactant properties, in
order to make the layer looser and more permeable (Geusens
et al., 2011).
Transfersomes R© are considered the first generation of highly
elastic or deformable vesicles (Cevc and Blume, 1992, 2001).
They are a novel type of liquid-state vesicles that consist of
phospholipids and an edge activator, which is often a single
chain surfactant (e.g., Sodium cholate, Span 60/65/80, and Tween
20/60/80) that destabilizes the lipid bilayers of the vesicles
and increases their deformability by lowering the interfacial
tension. This feature is thought to enable Transfersomes R© to
squeeze themselves through intercellular regions of the stratum
corneum under the influence of the transdermal water gradient.
They have been reported to penetrate intact skin in vivo with
an efficiency similar to subcutaneous administration, provided
that the elastic vesicles are topically applied in non-occlusive
conditions (Cevc and Blume, 1992, 2001; Elsayed et al., 2006,
2007).
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FIGURE 1 | Schematic representation of the different types of lipid-based vesicular delivery systems. (A) Conventional liposomes generally consist of a lipid
bilayer composed of phospholipids and cholesterol, which encloses an aqueous core. Both the lipid bilayer and the aqueous space can incorporate hydrophobic or
hydrophilic compounds, respectively (Hua and Wu, 2013). Liposome characteristics can be modified by the addition of surfactants to form (B) Transfersomes® and (C)
niosomes (depending on the ratio of phospholipid to surfactant), or relatively high concentrations of ethanol to form (D) ethosomes (Geusens et al., 2011; Vanic, 2014).
Ethosomes are another novel lipid carrier that has shown
enhanced skin delivery of encapsulated compounds (Touitou
and Ainbinde, 2000; Touitou et al., 2000). The ethosomal
system is mainly composed of phospholipids, a relatively
high concentration of ethanol (20–50%) and water. Rather
than destroying the lipid vesicular structure, Touitou et al.
demonstrated that the high alcohol concentration allows the
formation of soft, malleable and highly fluid vesicles (Touitou
et al., 2000). Ethanol is a well-known permeation enhancer
that is suggested to provide a synergistic mechanism with the
vesicles and skin lipids (Touitou et al., 2000; Elsayed et al.,
2006). The inclusion of ethanol may provide the vesicles with soft
flexible characteristics, which allow them tomore easily penetrate
into deeper layers of the skin. Phospholipid vesicles containing
ethanol may also influence the bilayer structure of the stratum
corneum to enhance drug penetration (Touitou and Ainbinde,
2000; Elsayed et al., 2006).
Introduction of permeation enhancers into the composition
of the newer lipid-based nano-delivery systems was thought
to increase both vesicle elasticity and deformability. These
vesicles also have the ability modify the stratum corneum to
promote impairment to its barrier function, with less well-
packed intercellular lipid structure to increase skin partitioning
of the drug (Elsayed et al., 2006). These novel vesicles
have demonstrated enhanced therapeutic potency compared to
conventional liposomes, where deeper levels of skin permeability
is required (Elsayed et al., 2007; Geusens et al., 2011).
Biomedical Applications of Lipid-based
Nano-delivery Systems
Topical drug delivery is an area of active research as it provides a
convenient and effective dosage form for the treatment of local
pathological conditions (dermal drug delivery) or as the site
for the administration of systemically active drugs (transdermal
drug delivery). Lipid-based vesicles have been used to encapsulate
a multitude of therapeutic agents, including drug molecules
(Hua and Wu, 2013; Bozzuto and Molinari, 2015), gene therapy
(Geusens et al., 2011; Monteiro et al., 2014), and bioactive
agents (e.g., growth factors and cytokines) (Monteiro et al.,
2014). Their use in topical formulations have demonstrated
improved treatment of inflammatory skin conditions such as
atopic dermatitis, psoriasis and acne; pathological conditions
of peripheral tissue such as inflammatory pain, melanoma, and
wound healing; and transdermal delivery of systemic agents for
vaccinations and conditions such as diabetes (insulin delivery)
and hormone replacement therapy (estrogen delivery) (Elsayed
et al., 2007; Schäfer-Korting et al., 2007; El Maghraby et al., 2008;
Geusens et al., 2011).
Based on recent findings, it has been demonstrated that
conventional liposomes are of little or no value as carriers for
transdermal drug delivery, as they tend to remain confined to
upper layers of the stratum corneum and are not able to penetrate
into the granular layers of the epidermis (Kirjavainen et al.,
1996, 1999; Honeywell-Nguyen and Bouwstra, 2005; Cosco et al.,
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2008; Geusens et al., 2011). Conventional liposomes have shown
increased effectiveness for local dermal drug delivery across
intact skin in comparison to free drug, with the ability to provide
prolonged drug release (Hua and Wu, 2013). For example,
topical application of loperamide HCl-encapsulated liposomal
gel, resulted in potent and prolonged analgesic and anti-
inflammatory activity in a rodent model of acute inflammatory
pain compared to controls (which did not show any therapeutic
effects) (Iwaszkiewicz and Hua, 2014). Topical application of
conventional liposomes has also been used for wound healing. It
should be noted that the skin barrier properties are compromised
with open wounds, which increases penetration and absorption
across the skin. For example, topical application of fibroblast
growth factor-1 (FGF-1) cDNA encapsulated within cationic
liposomes, demonstrated enhanced wound healing to the injured
skin of diabetic mice compared to controls (Sun et al., 1997).
The newer classes of lipid vesicles, including deformable
lipid vesicles and surfactant-based elastic vesicles, have generated
improved in vivo and in vitro skin delivery of various drugs and
bioactive agents for both dermal and transdermal drug delivery
(Elsayed et al., 2007; Schäfer-Korting et al., 2007; El Maghraby
et al., 2008; Geusens et al., 2011). For example, deformable lipid
vesicles have been studied for use as a gene delivery system for
topical application. Results have demonstrated enhanced in vivo
transfection efficiency of plasmid DNA and prolonged retention
times, with genes transported into several organs for 6 days
once applied on intact skin (Kim et al., 2004). In comparison
to deformable lipid vesicles, ethosomes are able to improve
skin delivery of drugs under both occlusive and non-occlusive
conditions (Elsayed et al., 2006, 2007).
Future Advances
Although the therapeutic advantages of lipid-based vesicles
for skin delivery of drugs and bioactive agents have been
supported by a multitude of in vitro and preclinical studies, the
development of these products through the R&D pipeline has not
progressed at the same pace. All the lipid platforms discussed
have entered clinical trials at various phases of development,
with mostly encapsulation of local anesthetics, anti-infectives, or
analgesics agents (Dubey et al., 2007; Elsayed et al., 2007; Nounou
et al., 2008). Currently, there is only one lipid-based drug
delivery platform for topical use on the market—estradiol topical
emulsion (Estrasorb R©) (Chiechi, 2004; Weissig et al., 2014). This
product uses micellar nanoparticle technology to deliver estradiol
to the blood circulation following topical application. In due
course, we should expect to see a number of additional products
for clinical use.
In order for the translational use of these carrier systems to the
clinic, several issues still have to be addressed. Firstly, the safety
of the different nano-delivery carriers following uptake needs
to be explored further. Studies focused on the nanotoxicology
of these delivery systems in human skin have been limited,
especially with the newer classes, and is likely to vary according
to the composition and size of the vesicles. For example, there
is a need to evaluate the short-term and long-term effects of
repeated applications of formulations containing relatively high
concentrations of ethanol or surfactants on the skin. Secondly,
structural and chemical stability during storage and following
topical application would need to be further optimized to
prevent premature release of the drug. Finally from a commercial
development point of view, simplification of drug delivery
design is required to allow efficient and reliable large-scale
manufacturing for regulatory purposes. As the preparation of the
newer classes of lipid vesicles involves similar methods to those
used in the preparation of conventional liposomes, this has made
the large-scale manufacturing and evaluation of such products
less challenging. Although innovative and efficient, translation of
these types of drug delivery systems to the clinic would need to
show significant therapeutic advantage over existing therapeutic
strategies, due to the added costs required in the manufacturing
process.
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